



Supplementary

Figure S1 CCF ratio is higher in MM-231 breast cancer cells




S1 CCF exists in different tumor cells. **A-B** MCF-10A, MCF-7, MM-231, HeLa, A375, DU145, PC3, SACC-83, SACC-lm cells were immunofluorescently stained with H3K9me3 to calculate the ratio of CCF, the arrow indicates CCF, Scalebars=10 μ m. Each experiment was repeated at least 3 times. Error bars, mean \pm SD, **, $P < 0.01$; ***, $P < 0.001$.

Figure S2 EZH2 affects CCF formation in breast cancer cells.




A-B MCF-7, MCF-7/ADR cells were immunofluorescently stained with H3K9me3 and H3K27me3 to calculate the ratio of CCF. CCF were indicated by arrows. Scale bars=10 μ m. Western blotting was used to detect the EZH2 level in MCF-7, MCF-7/ADR (**C**), MCF-7/ADR-shCtrl/MCF-7/ADR-shEZH2 cells (**D**). The ratio of CCF was calculated by immunofluorescence in MCF-7/ADR-shCtrl/MCF-7/ADR-shEZH2 cells (**D**), MCF-7/ADR cells treated with EPZ-6438 (3 μ M) for 72 h (**E**). **F** EZH2, H3K27me3 were immunofluorescently stained in MCF-7/ADR cells to observe the co-localization of EZH2 with CCF. **G** The ratio of H3K27me3⁺/EZH2⁺ and H3K27me3⁺/EZH2⁻ cells in the CCF of MM-231 and MCF-7/ADR cells were calculated respectively. Scale bars=5 μ m. Each experiment was repeated at least 3 times. Error bars, mean \pm SD, **, $P < 0.01$; ***, $P < 0.001$.

Figure S3 EZH2 affects cGAS-STING pathway activation in breast cancer cells.




Western blotting was used to detect the P-STING, STING and IL-6 level in MCF-7/ADR-shCtrl/MCF-7/ADR-shEZH2 (A), MM-231 cells treated with EPZ-6438 (3 μ M) for 72 h (B).

Figure S4 HMGA1 is a marker of CCF in breast cancer cells.



A siRNA is used to knock down HMG family proteins in MM-231 cells, and q-PCR is used to detect interference efficiency. **B** Western blotting was used to detect the HMGA1 level in MCF-7/ADR cells. **C** MCF-7/ADR cells were immunofluorescently stained with HMGA1 and H3K27me3 to observe the co-localization of HMGA1 and CCF, Scalebars=5 μ m. **D** The ratio of H3K27me3⁺/HMGA1⁺ and H3K27me3⁺/HMGA1⁻ cells in the CCF of MM-231 and MCF-7/ADR cells were calculated respectively, Scalebars=5 μ m. **E** MCF-7/ADR cells were immunofluorescently stained with HMGA1 and EZH2 to observe the co-localization of HMGA1 and EZH2, Scalebars=5 μ m. Each experiment was repeated at least 3 times. Error bars, mean \pm SD, **, $P < 0.01$; ***, $P < 0.001$.

Figure S5 EZH2 promotes breast cancer migration through CCF.



Wound-healing assay of MM-231 cells were treated with EPZ-6438 and cGAMP **(A)**, MM-231-dnMCAK cells treatment with EPZ-6438 **(B)**, MCF-7-EZH2 cells treatment with CCCP **(C)**.